Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences finite-lived intangible assets, net ($M) ($M)
Form 10-Q / 10-K Note 9 Goodwill and Intangible Assets
Latest, FY2025
14,678
Period ended Dec 31, 2025
Change on a year earlier
-14.0%
17,058 in FY2024
History
12 years
Since FY2014
Sources
12
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Finite-lived intangible assets, net ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 14,678 | -14.0% | Form 10-Q (filed 2026-08-06) ↗ |
| FY2024 | Dec 31, 2024 | 17,058 | -12.0% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 19,384 | +23.7% | Form 10-K (filed 2025-02-28) ↗ |
| FY2022 | Dec 31, 2022 | 15,674 | -10.6% | Form 10-K (filed 2024-02-23) ↗ |
| FY2021 | Dec 31, 2021 | 17,535 | +8.0% | Form 10-K (filed 2023-02-22) ↗ |
| FY2020 | Dec 31, 2020 | 16,236 | +29.4% | Form 10-K (filed 2022-02-23) ↗ |
| FY2019 | Dec 31, 2019 | 12,544 | -8.4% | Form 10-Q (filed 2020-05-06) ↗ |
| FY2018 | Dec 31, 2018 | 13,694 | -4.6% | Form 10-Q (filed 2019-11-05) ↗ |
| FY2017 | Dec 31, 2017 | 14,350 | +60.0% | Form 10-K (filed 2019-02-26) ↗ |
| FY2016 | Dec 31, 2016 | 8,971 | -8.6% | Form 10-K (filed 2018-02-27) ↗ |
| FY2015 | Dec 31, 2015 | 9,815 | -7.8% | Form 10-K (filed 2017-02-27) ↗ |
| FY2014 | Dec 31, 2014 | 10,641 | – | Form 10-K (filed 2016-02-24) ↗ |
Breakdown
What makes up finite-lived intangible assets, net ($m)
- Finite-lived intangible assets, gross ($M)31,888 · FY2025
- Finite-lived intangible assets — Accumulated amortization ($M)17,211 · FY2025
- Trodelvy (sacituzumab govitecan) intangible asset — Net carrying value ($M)7,566 · FY2025
- Sofosbuvir (Epclusa / Harvoni / Vosevi) intangible asset — Net carrying value ($M)2,272 · FY2025
- Yescarta (axicabtagene ciloleucel) intangible asset — Net carrying value ($M)3,983 · FY2025
- Hepcludex (bulevirtide) intangible asset — Net carrying value ($M)430 · FY2025
- Other finite-lived intangible assets — Net carrying value ($M)428 · FY2025
Cite this data
StockData. (2026). Gilead Sciences Finite-lived intangible assets, net ($M) ($M), annual FY2014–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/intang_finite_net
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.